A Novel, Selective and Efficacious Nanomolar Pyridopyrazinone Inhibitor of BRAF
نویسندگان
چکیده
Signal Transduction Team, Section of Cell and Molecular Biology, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK. Gene and Oncogene Targeting Team, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK Corresponding authors.
منابع مشابه
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.
Oncogenic BRAF is a critical driver of proliferation and survival and is thus a validated therapeutic target in cancer. We have developed a potent inhibitor, termed 1t (CCT239065), of the mutant protein kinase, (V600E)BRAF. 1t inhibits signaling downstream of (V600E)BRAF in cancer cells, blocking DNA synthesis, and inhibiting proliferation. Importantly, we show that 1t is considerably more sele...
متن کاملDiscovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. However, the majority of responses are transient, and resistance is often associated with pathway reactivation of the extracellular ...
متن کاملTitle: Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAF Colorectal Cancer Authors and Affiliations:
Purpose: BRAF mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Whereas selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAF CRC. Experimental Design: We examined phosphatidyl inositol 3-kinase (PI3K)/ma...
متن کاملCancer Therapy: Preclinical Concomitant BRAFandPI3K/mTORBlockade IsRequired for Effective Treatment of BRAF Colorectal Cancer
Purpose: BRAF mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment ofmelanoma, comparable efforts inCRChave been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAF CRC. Experimental Design: We examined phosphoinositide 3-kinase (PI3K)/mTOR sign...
متن کاملNovel Group of Imidazole Derivatives as Atypical Selective Cyclooxygenase-2 Inhibitors: Design, Synthesis and Biological Evaluation
In this study, a new series of 5-substituted 1-benzyl-2-(methylsulfonyl)-1-H-imidazolewith atypical structure-activity relationship was designed, synthesized, and biologicalevaluated as selective cyclooxygenase-2 inhibitors. Docking studies revealed that althoughthe pharmacophoric substitute of the compound 5b, methylsulfonyl group, has been directlyattached to the central ring, it is in the sa...
متن کامل